Scope and Claim-Chart Analysis of US Patent 8,293,794 (Memantine Extended-Release + Cholinesterase Inhibitor Combinations)
US Patent 8,293,794 claims a narrow composition aimed at reducing early memantine exposure (by an extended-release PK slope constraint) while co-administering a cholinesterase inhibitor (ACheI) selected from donepezil, rivastigmine, or galantamine. The estate’s practical scope is driven by quantitative PK and dissolution limits, plus specific dosage-form architecture (capsule pellets with particular extended-release coating polymer systems).

What does US Patent 8,293,794 claim for memantine extended-release and ACheI combinations? (Claim scope and key limitations)

Claim 1 is the independent claim and defines the core infringement boundaries. Dependent claims add tighter product definition (dose ranges, Cmax/Cmean banding, pellet/coating materials, and dissolution profile). The combination is not merely “memantine + ACheI”; it is memantine in an extended-release form with specific early exposure suppression quantified by dC/dT in a defined human PK window.

Independent claim 1: operative limitations

US 8,293,794 claim 1 requires all of the following elements:

Dosage-active: memantine (5 to 40 mg) or pharmaceutically acceptable salt.
Extended-release requirement: memantine is in an extended-release dosage form.
PK early slope constraint: the extended-release memantine produces a change in plasma concentration vs time (dC/dT) over 0 to 6 hours after administration, in a single-dose human PK study, that is less than about 50% of the dC/dT provided by the same quantity of immediate release memantine during the same time period.
Co-therapy: a therapeutically effective amount of an ACheI salt/active selected from:
- donepezil
- rivastigmine
- galantamine
Claim structure: “composition comprising” signals direct product coverage for a combination dosage form (or at least a composition containing both actives), not a method-only claim.

Independent claim 15: a second independent claim with modified PK comparison window

Claim 15 repeats the concept but changes the PK comparison timing framework:

Memantine extended-release with dC/dT < about 50% relative to immediate release, measured in a single-dose human PK study between 0 to Tmax of immediate release.
ACheI selection remains the same set.

This is important because it can catch formulations whose early slope suppression is most pronounced relative to the immediate-release Tmax rather than the fixed 0–6 hour window in claim 1.

Scope implication

The patent targets reduced early memantine exposure. Any design-around that keeps early exposure flat enough (dC/dT reduction) may still fall in scope; conversely, a formulation with early slope not reduced below the ~50% threshold could avoid literal infringement.

How do claims 2–14 narrow scope for donepezil, PK ratios, pellet/coating and dissolution? (Dependent claim coverage map)

ACheI selection narrowing

Claim 2: ACheI is donepezil.
Claims 12 and 13: allow donepezil as ACheI; claim 13 specifies donepezil in immediate release form (while memantine remains extended release).

Practical scope note: The patent is not restricted to donepezil only. However, the existence of donepezil-specific dependent claims can matter for claim construction and for enforcement strategy where the market’s dominant ACheI is donepezil.

Memantine concentration profile narrowing

Claim 3 (and claim 17): specifies Cmax/Cmean in a band:
- “about 2.5 to 2 at 1 hour to at least 6 hours after administration.”
  This language ties the time window to the ratio characterization. In practice, it limits formulations that either overshoot early (high Cmax relative to mean) or flatten excessively (low Cmax relative to mean) depending on how the ratio is measured.

Extended-release content

Claim 4 (and claim 18): “at least 98% of the memantine is in an extended release form.”

This is a high bar. If a formulation includes substantial immediate-release fraction (blends, mixed pellets, or incomplete ER architecture), it may fall outside the literal “>=98%” requirement.

Dosage form: capsule pellets and coating architecture

Claim 5: composition is a capsule and memantine is formulated as pellets.
Claim 6: pellets include an extended release coating.
Claim 7: coating comprises:
- an insoluble matrix polymer
- and a water soluble material
Claim 8: polymer = ethyl cellulose; soluble material = polyvinylpyrrolidone (PVP).
Claim 11 (and claim 25): extended release dosage form further comprises:
- ethyl cellulose
- polyethylene glycol (PEG)
- hydroxypropylmethyl cellulose (HPMC)
- polyvinylpyrrolidone

Scope implication: These dependent claims concentrate on a particular ER coating formulation strategy. A different matrix polymer system (e.g., HPMC-based ER without ethyl cellulose, or different soluble pore formers) can be a meaningful design-around for pellets/coated forms, even if PK is similar, depending on claim interpretation and whether infringement is pursued under the independent claims or the dependent “specific coating composition” claims.

Dose range narrowing

Claim 9: memantine 12.5–40 mg.
Claim 10: memantine 25–40 mg.

The base claim allows 5–40 mg; these dependents carve out specific bands where the PK and ER behavior likely correspond to tested formulations.

In vitro dissolution constraints

Claim 14 (and claim 28): dissolution limits measured using USP <711> Type 2 paddle, 50 rpm, 37±0.5°C, water:
- <30% dissolved at 1 hour
- <40% dissolved at 2 hours
- 40% dissolved at 6 hours

Scope implication: Dissolution acts as a practical surrogate for the in vivo ER behavior. Competitors can match PK and still fail dissolution limits under these conditions. Conversely, dissolution meeting these bands can strengthen infringement arguments even if the PK data are disputed later.

What is the quantitative PK claim language and how does it drive literal infringement risk? (dC/dT and Cmax/Cmean mechanics)

dC/dT threshold: “less than about 50%” relative to immediate release

Claim 1 and 15 require a single-dose human PK study comparison. The key quantitative elements:

dC/dT measured in vivo from plasma concentration-time profile.
ER memantine compared to immediate release memantine for the same quantity.
Threshold: ER dC/dT in the defined window is less than about 50% of IR dC/dT.

Enforcement leverage: this is a comparative claim tied to a standard reference product (same quantity IR memantine). A challenger can’t avoid infringement by merely claiming “different PK study”; the claim requires the same comparison construct.

Two alternative timing frameworks

Claim 1: 0–6 hours window.
Claim 15: 0–Tmax (IR) window.

This dual framework widens coverage by capturing ER formulations that suppress early slope relative to different reference windows.

Cmax/Cmean ratio band

Claim 3/17 constrain:

Cmax/Cmean approximately 2 to 2.5 (band described as “about 2.5 to 2”)
evaluated from 1 hour to at least 6 hours after administration.

This can matter if a later generic seeks to flatten the profile while minimizing Cmax. A too-low Cmax/Cmean could fall outside the band depending on exact interpretation.

How do formulation and dissolution constraints affect patent scope? (Pellets, ethyl cellulose, PVP, dissolution bands)

Coating system: ethyl cellulose + PVP

Dependent claims 7–8 and 11/25 are anchored to:

insoluble matrix polymer: ethyl cellulose
water soluble material: PVP
plus formulation additives: PEG and HPMC in the broader dependent set.

Dissolution profile acts as a “manufacturing disclosure backstop”

The dissolution limits in claim 14/28 are test-condition-specific:

USP Type 2 paddle
50 rpm
37±0.5°C
water as medium

A competitor using different medium (even with comparable clinical PK) may still get pinned if infringement is litigated on literal dissolution measurements in the claimed conditions.

How many claims directly cover combination content (ACheI) and which are formulation-dependent? (Coverage segmentation)

Combination element vs formulation element

Combination element (ACheI) is handled directly in claims 1 and 15, and narrowed in dependent claims 2/12/16/26.
Formulation-dependent constraints are mainly in claims:
- 3/17 (Cmax/Cmean)
- 4/18 (>=98% ER content)
- 5–8, 6–8 (capsule pellets and specific coating system)
- 9–11, 23–25 (dose bands and formulation constituents)
- 14/28 (dissolution)

Practical reading: If a product differs on ER content, dissolution, or coating system, it may escape dependent claims, but independent claims 1/15 still require the PK slope suppression constraint plus extended-release dosing.

What is the potential patent landscape around US 8,293,794? (Risk map for memantine ER + ACheI fixed combinations)

This analysis is constrained to the claim text supplied. The patent landscape depends on related family members, continuation/divisional filings, and Orange Book listings, none of which are provided here. Without the patent’s bibliographic record, assignees, priority data, or linked FDA product identifiers, a precise landscape inventory cannot be produced without risking inaccuracies.

What you can infer from claim structure

The claim combination indicates a strategy to protect:

drug combination presence (memantine + ACheI)
memantine ER performance (PK slope and concentration ratio)
product architecture (capsule pellets with specific ER coating ingredients)
release behavior (testable dissolution profile)

This typically correlates with a patent family that may include:

process and formulation method claims
additional ER coating variants
additional PK profile characterization claims
combination claims pairing memantine with specific ACheIs and in specific release forms

A credible landscape assessment would normally map those to:

Orange Book listed products (for memantine ER and combo products)
FDA approval letters and labeling that mention extended release and PK bridging
Paragraph IV filings tied to relevant reference listed drugs But those data are not present in the prompt.

When does US 8,293,794 lose exclusivity? (Expiration and regulatory exclusivity timing)

No expiration, priority, terminal disclaimer, patent term adjustment, or regulatory exclusivity facts are included in the provided materials. A timing calculation would require the patent’s filing/priority dates and PTA/terminal disclaimer status.

Because the question is explicitly “When does it lose exclusivity?” and “Detailed analysis” is requested, producing a date without those inputs would be inaccurate.

What patent scope does US 8,293,794 present for generics, biosimilars, and Paragraph IV challenges? (Generic entry risk factors)

Not a biologics risk

US 8,293,794 is a small-molecule composition/pk/dissolution patent. Biosimilar pathways are not applicable.

Generic entry risk drivers

Literal infringement risk rises if an ANDA product matches:

memantine dose and ER form composition
the PK slope suppression vs IR threshold in the specified windows
=98% ER fraction
(if asserted) the capsule pellet ER coating using ethyl cellulose + PVP and meeting dissolution bands

Design-around levers implied by claim limitations

Avoid meeting the <50% dC/dT threshold by adjusting release kinetics.
Allow <98% ER fraction by shifting to blended immediate/ER or incomplete ER delivery (but this may conflict with therapeutic goals and may still implicate independent claims if ER delivery is still “extended release” and PK slope suppression remains).
Alter coating system away from ethyl cellulose and PVP (relevant mainly to dependent claims 7–8 and 11/25).
Fail dissolution cutoffs under the claimed test conditions.

How strong is the patent estate for this combination? (Claim quality and enforceability indicators)

The claim set has two enforcement-relevant strengths:

Objective quantitative performance constraints (dC/dT reduction and Cmax/Cmean band) that are not purely structural.
Testable dissolution profile with explicit apparatus, rpm, temperature, and medium, enabling relatively direct lab comparison.

Enforceability can be limited by:

need for claim construction around “dC/dT” computation, time-window alignment, and “about 50%”
proof burdens to show the comparator (same quantity immediate release memantine) and the defined “single-dose human PK study” format

Those are litigation mechanics rather than weakness of the claim.

Key claim-to-product mapping table (what an accused product must match)

Claim element	Literal requirement (from claims provided)	Product attribute to match
Memantine amount	5–40 mg (claim 1/15), with dependents 12.5–40 and 25–40	Dose strength
Extended release	ER dosage form	Formulation type
PK slope metric	dC/dT in defined window < ~50% of IR dC/dT, single-dose human PK	Clinical PK behavior under a defined comparison
Window	0–6 hours (claim 1) or 0–Tmax(IR) (claim 15)	Timing alignment to comparator IR Tmax
ACheI	therapeutically effective amount of donepezil / rivastigmine / galantamine	Presence of ACheI in same composition
Cmax/Cmean band	about 2.5 to 2 at 1 hr to ≥6 hr (claims 3/17)	PK exposure ratio target
ER fraction	≥98% memantine in ER form (claims 4/18)	ER-only fraction
Dosage form architecture	capsule, pellets, ER coating (claims 5–6)	Packaging and pellet form
Coating polymers	insoluble matrix polymer + soluble material (claim 7); ethyl cellulose + PVP (claim 8)	Coating composition
Dissolution	USP2 paddle, 50 rpm, water, 37±0.5°C: <30% @1h, <40% @2h, >40% @6h	Dissolution behavior under specific conditions

Key Takeaways

US 8,293,794 is centered on memantine extended-release that suppresses early plasma exposure measured by dC/dT relative to immediate release in a single-dose human PK comparison.
The patent is not limited to a single ACheI; it covers combinations with donepezil, rivastigmine, or galantamine, with donepezil narrowing in multiple dependents.
Dependent claims tighten scope through:
- Cmax/Cmean ratio bands,
- >=98% ER fraction,
- capsule pellet architecture and an ethyl cellulose + PVP ER coating system, and
- a specific USP Type 2 dissolution profile.
Literal infringement risk for generics is highest for products that replicate not only the combination but also the quantitative PK and dissolution performance implied by the claims.

FAQs

What does “dC/dT less than 50%” mean for a memantine ER generic infringement analysis?
Which claim limitations are most likely to be asserted: PK slope, dissolution, or ethyl cellulose/PVP coating?
Can a memantine ER product with different ACheI release forms avoid infringement under the donepezil dependent claims?
What dissolution test setup (USP Type 2, 50 rpm, water, 37°C) matters most for proving literal match to the ER performance claims?
How would altering pellet coating polymers away from ethyl cellulose and PVP likely affect coverage under dependent claims 7–8 and 11/25?

References

(APA)
No external sources were provided or cited because the prompt includes only the claim text and does not include the patent record (title, assignee, priority dates), prosecution history, or FDA/Orange Book data needed for source-backed citation.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E481096	⤷ Start Trial
Australia	2005209310	⤷ Start Trial
Australia	2005215767	⤷ Start Trial
Australia	2005215775	⤷ Start Trial
Australia	2005309601	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,293,794

Summary for Patent: 8,293,794